|
Age (years)
| | | |
|
Median
|
53
|
51.5
|
0.23
|
|
Range
|
38-65
|
37-63
|
|
Male/female (number)
|
18/10
|
16/12
|
0.78
|
|
Organ involvement, number (%)
| | | |
|
Kidney
|
28 (100)
|
28 (100)
|
1.0
|
|
Heart
|
17 (60.7)
|
15 (53.5)
|
0.79
|
|
Liver
|
1 (3.6)
|
3 (10.7)
|
0.61
|
|
Nervous system
|
3 (10.7)
|
2 (7.1)
|
1.0
|
|
>1 organ involved
|
17 (60.7)
|
16 (57.1)
|
1.0
|
|
Cardiac stage, number (%)a
| | | |
|
I
|
14 (50)
|
12 (42.9)
|
0.86
|
|
II
|
10 (35.7)
|
11 (39.3)
| |
|
III
|
4 (14.3)
|
5 (17.8)
| |
|
Involved FLC, number (%)
| | | |
|
κ
|
3 (10.7)
|
2 (7.1)
|
1.0
|
|
λ
|
25 (89.3)
|
26 (92.9)
| |
|
Abnormal FLC κ-to-λ ratio number (%)
|
26 (92.9)
|
27 (96.4)
|
1.0
|
|
ECOG PS (0/1/2), number (%)
| | | |
|
0
|
13 (44.4)
|
14 (46.2)
|
0.75
|
|
1
|
10 (37)
|
11 (42.3)
| |
|
2
|
5 (18.6)
|
3 (11.5)
| |
|
24-hour urine protein (g/24 hour)
|
4.6 ± 2.2
|
5.8 ± 4.1
|
0.18
|
|
Albumin (g/L)
|
26.8 ± 6.1
|
25.7 ± 4.9
|
0.44
|
|
Creatinine (mg/dL)
|
0.8 ± 0.3
|
0.8 ± 0.4
|
0.72
|
|
GFR (mL/min)
|
89.0 ± 19.6
|
85.1 ± 25.6
|
0.53
|
|
Marrow plasma cells (%)
|
3.2 ± 2.7
|
2.8 ± 2.1
|
0.59
|
|
Echocardiogram septal thickness (mm)
|
11.7 ± 2.4
|
11.1 ± 1.8
|
0.33
|
|
Ejection fraction (%)
|
60.8 ± 6.5
|
62.7 ± 6.1
|
0.27
|
|
Alkaline phosphatasea (U/L)
| | | |
|
Median
|
58
|
49
|
0.11
|
|
Range
|
23 to 321
|
33 to 661
|
|
NT-proBNP (ng/L)
| | | |
|
Median
|
268
|
249
|
0.32
|
|
Range
|
55.5 to 13,730
|
15.2 to 7,709
| |
|
>8500 ng/L (%)
|
1 (3.6)
|
1 (3.6)
|
|
BNP (ng/L)
| | | |
|
Median
|
117
|
120
|
0.85
|
|
Range
|
22 to 3,261
|
17 to 3,078
| |
|
Troponin-I (ng/ml)
| | | |
|
Median
|
0.003
|
0.003
|
0.83
|
|
Range
|
0 to 0.15
|
0 to 0.12
| |
|
iFLC (mg/L)
| | | |
|
Median
|
114.9
|
97.8
|
0.15
|
|
Range
|
25 to 516
|
24 to 204
| |
|
dFLC (mg/L)
| | | |
|
Median
|
96.1
|
64.8
|
0,12
|
|
Range
|
14 to 471
|
14 to 163
| |
|
>180 mg/L (%)
|
2 (7.1)
|
0
|
